The World Health Organisation (WHO) has welcomed the latest findings from the Purpose 2 trial on long-acting injectable lenacapavir (LEN) for HIV prevention. LEN is being explored as a potential long-acting pre-exposure prophylaxis (PrEP) for HIV prevention. WHO notes that an interim analysis, announced on September 12, 2024, demonstrated the drug’s remarkable efficacy in preventing […]
